16 Apr 2015 15:44
Cathay International Holdings Limited
("Cathay" or the "Company")
Annual Report and Accounts
Hong Kong, 16 April 2015 - Cathay International Holdings Ltd. (LSE: CTI.L),an investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China, today announces that its Annual Report and Accounts for the financial year ended 31 December 2014 together with the Notice of Annual General Meeting ("AGM"), Form of Direction and Form of Proxy for its forthcoming AGM have been posted to shareholders.
These documents will also be uploaded to the National Storage Mechanism and will shortly be available for inspection at www.Hemscott.com/nsm. In addition, the documents will be available on the Cathay International Holdings website at http://www.cathay-intl.com.hk and may also be obtained from the Company Secretary.
The AGM will be held at the Company's Hong Kong Office at Suites 1203-4, 12/F, Li Po Chun Chambers, 189 Des Voeux Road Central, Hong Kong on 5 June 2015 at 10:00 a.m. (Hong Kong time).
For further enquiries, please contact:
Cathay International Holdings Limited Eric Siu (Finance Director) Patrick Sung (Director and Controller) |
Tel: +852 2828 9289 |
Consilium Strategic Communications Mary-Jane Elliott / Amber Bielecka / Matthew Neal / Lindsey Neville
|
Tel: +44 (0)203 709 5708 Cathay@consilium-comms.com
|
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China ("PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in China and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, China's leading specialty pharmaceutical company focused on rheumatology and dermatology; Haizi, a company engaged in the manufacture, marketing and sales of inositol and its by-product, di-calcium phosphate; Yangling, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment.
For more information please visit the Company's website: www.cathay-intl.com.hk